FDAnews
www.fdanews.com/articles/197966-asuragen-gets-ce-mark-for-spinal-muscular-atrophy-assay

Asuragen Gets CE Mark for Spinal Muscular Atrophy Assay

July 8, 2020

Asuragen has received CE mark certification in the U.S. for its AmplideX spinal muscular atrophy in vitro diagnostic assay.

The AmplideX SMA Plus Kit is used for diagnosis of the rare genetic disorder and can identify asymptomatic carriers who may pass the disease on to their children.

The polymerase chain reaction test runs on Thermo Fisher Scientific's Applied Biosystems Genetic Analyzers and delivers results in four hours.

View today's stories